Mecure Industries PLC
NNSENG:MECURE56.20
NGN
0.00
(0.00%)
ISIN
NGMECURE0006
Return %
Stock
S&P 500
1Y
97.89
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Anderline Ndidi Dukor
- Full Time Employees
- 195
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Oshodi Nigeria
- IPO Date
- Nov 7, 2023
- Website
- mecure.com
- Similar Companies
- Business
- Mecure Industries PLC is a Nigeria-based pharmaceutical manufacturing and healthcare company engaged in the research, formulation, manufacturing, marketing, and distribution of generic pharmaceuticals, over-the-counter medicines, and nutraceutical products. Founded in 2005 and headquartered in Lagos, Nigeria, the company operates primarily within the healthcare and life sciences sector, supplying essential human therapeutics to commercial distributors, retail pharmacies, and institutional healthcare providers across Nigeria and neighboring West African markets. The company offers a diversified therapeutic portfolio spanning multiple product categories and dosage forms, including solid dosage forms such as analgesics, antipyretics, anti-inflammatory agents, antimalarials, broad-spectrum anti-infectives, antihypertensives, and oral antidiabetic tablets and capsules; liquid oral formulations comprising pediatric suspensions, expectorants, cough syrups, antacid suspensions, and digestive remedies; dedicated beta-lactam antibiotic formulations such as amoxicillin, ampicillin-cloxacillin combinations, and clavulanate formulations in capsule and dry powder suspension presentations; and nutraceuticals, multivitamins, and dietary health supplements formulated as effervescent tablets, capsules, and oral syrups. In addition to its proprietary branded generic product lines, the company provides third-party contract manufacturing, formulation development, quality assurance testing, and secondary packaging services for multinational pharmaceutical brands and public health organizations. In recent strategic developments, Mecure Industries PLC completed its public listing by introduction on the Nigerian Exchange under the ticker MECURE, listing four billion ordinary shares to expand its institutional investor base and enhance market transparency. Operationally, the company has expanded its manufacturing footprint with substantial capital investments into specialized production lines, including dedicated beta-lactam manufacturing capabilities and a state-of-the-art oncology pharmaceutical manufacturing plant designed to produce solid oral cancer therapies locally in Nigeria. These strategic initiatives are supported by continued investments in regulatory compliance, automated packaging technology, and the widening of its nationwide cold-chain and pharmaceutical logistics network to strengthen domestic drug security and support cross-border trade across the Economic Community of West African States region.